Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines
Phase 1
Completed
- Conditions
- Prophylaxis Herpes Simplex
- Interventions
- Biological: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141Biological: Herpes simplex virus containing gD-Alum
- Registration Number
- NCT00698490
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of the study is to compare, in healthy HSV seronegative and HSV seropositive subjects, the humoral and cellular immune response of herpes simplex candidate vaccines containing gD from two different cell lines and using gD-Alum as control.
- Detailed Description
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
- Between 18 and 45 years of age
- Written informed consent
- Female volunteers must be using contraception and should avoid becoming pregnant for the duration of the vaccination course
- Serology: Groups 1, 3, 4 and 5: HSV-1 AND HSV-2 seronegative (by gD2 ELISA); Group 2: HSV seropositive by gD2 ELISA before entry
Exclusion Criteria
- Any previous vaccination against Herpes simplex.
- Any previous administration of MPL.
- Pregnancy or lactation.
- Patient is immuno-compromised or is receiving immuno-modifying therapy of any kind.
- Clinical signs of acute or febrile illness at the time of entry into the study.
- Any administration of immunoglobulins during the vaccination course or within one month of vaccination.
- Any vaccination within one week of study vaccination.
- Previous known hypersensitivity to vaccination or to any component of the vaccine.
- Simultaneous participation in any other clinical trial with an investigational drug or vaccine. Subjects currently in a follow-up period of a vaccine study can be included.
- Recent history of alcoholism or drug abuse (within the past 6 months).
- Life-threatening or serious cardiac (NYHA grades III-IV), gastrointestinal, hepatic, renal, hematological or immunological disorder which, in the opinion of the investigator, would preclude entry into the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group C Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141 HSV-seronegative subjects Group D Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141 HSV-seronegative subjects Group A Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141 HSV-seronegative subjects Group B Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141 HSV-seropositive subjects Group E Herpes simplex virus containing gD-Alum HSV-seronegative subjects
- Primary Outcome Measures
Name Time Method To evaluate in initially HSV-seronegative subjects the GMT's and the seroconversion rates of anti-gD2 antibodies (ELISA) After the second and third doses of each vaccine To evaluate in initially HSV-seronegative subjects, the GMT and the seropositivity rate of anti-HSV-2 neutralizing antibodies To evaluate the cell-mediated immune (CMI) response (lymphoproliferation, secretion of interleukin 2 and γ interferon) After the second and third dose of each vaccine formulation To evaluate, in initially seronegative subjects and in initially seropositive subjects, the incidence and intensity of solicited local and general signs and symptoms During 3 days after each dose of each vaccine To evaluate in initially seropositive subjects, the GMT and the seropositivity rate of anti-gD2 antibodies (ELISA) and of anti-HSV-2 neutralizing antibodies After 2 and 3 doses of vaccines
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
GSK Clinical Trials Call Center
🇧🇪Gent, Belgium